85 completed, 19 terminated, 6 withdrawn, 3 active not recruiting. 74 Phase 2, 43 Phase 1, 8 Phase 3.
Follow ixabepilone: new trials by email Literature Review of ixabepilone trials Research Report on ixabepilone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. Ixabepilone Injection - Metastatic Breast Cancer | Phase 2 | Terminated | Allarity Therapeutics | 13 | 2021-03-01 | 2026-03-12 |
| Breast Cancer Treatment Based on Organ-like Culture Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids | Unknown | Xijing Hospital | 300 | 2019-01-02 | 2019-04-24 | |
| Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy Taxane, Vinorelbine, Ixabepilone - Breast Cancer, Breast Neoplasms | Terminated | University of Wisconsin, Madison | 5 | 2018-01-29 | 2024-06-25 | |
| Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Ixabepilone, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Yale University | 78 | 2017-04-03 | 2024-05-14 |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine NKTR-102, Eribulin, Ixabepilone - Metastasis, Breast Cancer | Phase 3 | Completed | Nektar Therapeutics | 178 | 2016-11-01 | 2023-04-14 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer Ixabepilone, Capecitabine, Motesanib - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-12-01 | 2025-05-02 | |
| Ixabepilone and SBRT For Metastatic Breast Cancer IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY - METASTATIC BREAST CANCER | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2013-08-01 | 2020-08-20 | |
| PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer Anthracycline based chemotherapy, taxane-based chemotherapy - Breast Cancer | Phase 2 | Withdrawn | Jenny C. Chang, MD | 2012-07-01 | 2023-02-02 | |
| Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Paclitaxel, Docetaxel, Abraxane - Breast Neoplasms, Breast Cancer | Phase 2 | Completed | The Methodist Hospital Research Institute | 38 | 2011-09-01 | 2023-01-23 |
| A Study of LY2523355 in Participants With Breast Cancer LY2523355, ixabepilone, pegfilgrastim - Metastatic Breast Cancer | Phase 2 | Completed | Eli Lilly and Company | 39 | 2011-08-01 | 2019-09-18 |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Ixabepilone, Pharmacological Study, Temsirolimus - Adult Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 22 | 2011-06-27 | 2026-09-11 |
| A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Lapatinib and ixempra - Recurrent Endometrial Cancer | Phase 1 | Unknown | Hung-Hsueh Chou | 24 | 2011-03-01 | 2011-10-19 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Ixabepilone, Laboratory Biomarker Analysis - Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2010-11-01 | 2019-08-08 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Ixabepilone, Laboratory Biomarker Analysis - Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2010-09-07 | 2019-08-08 |
| Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer vorinostat, ixabepilone, laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | City of Hope Medical Center | 56 | 2010-06-02 | 2026-10-26 |
| Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery ixabepilone, adjuvant therapy, intensity-modulated radiation therapy - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2010-05-26 | 2020-08-20 | |
| Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) ixabepilone, bevacizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Terminated | Providence Health & Services | 6 | 2010-02-01 | 2015-09-07 |
| Ixabepilone + Carboplatin Metastatic Breast Cancer Ixabepilone, Carboplatin - Metastatic Breast Cancer | Phase 2 | Completed | US Oncology Research | 103 | 2010-01-01 | 2016-12-07 |
| Study of Pazopanib and Ixabepilone in Patients With Solid Tumors Pazopanib, Ixabepilone - Breast Cancer, Lung Cancer | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 31 | 2009-12-01 | 2017-12-28 |
| Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer Ixabepilone - Stomach Neoplasms | Phase 2 | Completed | R-Pharm | 58 | 2009-11-01 | 2020-10-28 |
Showing 20 of 116. Sign in to see all of them.
Breast Neoplasms (47) · Neoplasms (10) · Prostatic Neoplasms (8) · Neoplasm Metastasis (6) · Breast Neoplasms, Male (5) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Ovarian Epithelial (5) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Ovarian Neoplasms (4) · Sarcoma (4) · Burkitt Lymphoma (3) · Carcinoma, Renal Cell (3) · Colonic Neoplasms (3) · Endometrial Neoplasms (3)
National Cancer Institute (NCI) (30) · R-Pharm (28) · Memorial Sloan Kettering Cancer Center (6) · SCRI Development Innovations, LLC (5) · Bristol-Myers Squibb (4) · SWOG Cancer Research Network (3) · Montefiore Medical Center (2) · The Methodist Hospital Research Institute (2) · University of Texas Southwestern Medical Center (2) · Accelerated Community Oncology Research Network (1) · Albert Einstein College of Medicine (1) · Allarity Therapeutics (1) · Brown University (1) · Cedars-Sinai Medical Center (1) · City of Hope Medical Center (1)
United States (101) · Italy (14) · France (12) · Spain (9) · United Kingdom (7) · Argentina (6) · Belgium (6) · Canada (6) · Germany (6) · Greece (6) · Australia (5) · South Korea (5) · Taiwan (5) · Japan (4) · Russia (4)
Denise A Yardley, M.D. (2) · Manish A. Shah, MD (2) · Sridhar Mani, MD (2) · AeRang Kim, MD (1) · Agustin Garcia, MD (1) · Alessandro D. Santin, MD (1) · Andrea Harzstark (1) · Andres Forero-Torres, MD, CSU (1) · Angel A Rodriguez, MD (1) · Angela Davies, MD (1) · Anna Pavlick (1) · Antonio T Fojo, M.D. (1) · Arkaduisz Z Dudek, MD (1) · Asal Rahimi, MD (1)
PMID 21128114, PMID 21937232, PMID 24472478, PMID 12114401, PMID 14504052, PMID 15735119, PMID 16314632, PMID 16699973, PMID 17261851, PMID 17606971, PMID 17968020, PMID 18451235, PMID 19075272, PMID 19349545, PMID 20098694, PMID 20179242, PMID 20357034, PMID 22947511, PMID 23589560, PMID 23935969, PMID 23939283, PMID 24048789, PMID 25091619, PMID 25913905, PMID 25925990, PMID 26056183, PMID 27312051, PMID 28620884, PMID 28679644, PMID 29522361, PMID 31074641, PMID 33541735, PMID 34616010, PMID 35149854, PMID 35552364, PMID 35658479, PMID 37185961, PMID 37883329, PMID 39169033, PMID 39516558
U10CA027469 (5), U10CA021115 (4), N01CM62201 (3), P30CA013330 (3), U10CA180868 (3), 2008 (2), N01CM62202 (2), N01CM62206 (2), P30CA014599 (2), P30CA015083 (2), N01CM17103 (1), N01CM17104 (1), N01CM62204 (1), N01CM62209 (1), P30CA006516 (1)